Authors: Liubov Sichel, Natalya A Timoshok, Valentyn S Pidgorskyy, Nykolay Y Spivak
Publication: Journal of Probiotics & Health
Background: Mechanisms of action and optimal doses have not yet been determined for the immunomodulator del-IMMUNE V®, a supplement containing dry fermented cell lysate and DNA fragments of the probiotic strain Lactobacillus rhamnosus V (DV Strain).
Objective: To study the mechanisms of del-IMMUNE V® immunomodulation and to investigate dose-dependent effects on immunoregulatory cytokines production in vivo and in vitro.
Design: One hundred forty inbred laboratory mice with body masses ranging from 14-16 grams were divided into 7 test groups. Groups I, II, and III received 0.5 ml of aqueous solution of del-IMMUNE V® by mouth in doses of 5, 50, and 500 µg per mouse, respectively, for 5 days at 24-hour intervals. Group IV mice received 0.5 ml Bifidim suspension by mouth in a dose of 50 µg/mouse on the same schedule. Group V mice (control group) received 0.15 M NaCl. Group VI and VII mice received a single dose of 50 µg/mouse del-IMMUNE V® (Group VI) or Bifidim (Group VII) on day 1 of the test period. Eight hours after administration and every 24 hours thereafter for 5 days, blood serum, peritoneal exudate macrophages, and splenocytes were obtained from each group for testing. Interferonogenous activity of cultured splenocytes and serum levels of interferon were assessed.
Results: Groups I-IV showed a marked increase of IFN levels in blood serum after administration of del-IMMUNE V® or Bifidim; the optimal daily dose was found to be 50 µg/mouse. The highest serum IFN level was reported 24 hours after administration. The control group remained unchanged. Maintenance of elevated circulating IFN was possible only through repeated administration.
Conclusions: In this study, a 50 µg/mouse dose of del-IMMUNE V® was shown to actively induce IFN and moderately stimulate the production of TNF, showing significant promise as an immunomodulating preparation.